Andrew Futreal
Chair and Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (26)
S1. Heatmap of unsupervised hierarchical clustering of the top 1000 most variable genes.S2. Violin plots showing the expression levels of genes previously identified as differentially expressed genes between primary and recurrent tumors in Haltia et al., 2020.S3. Gene set enrichment analysis performed with GO terms and KEGG pathways showing that primarily immune-related and hormone-regulated gene sets expression are altered between primary and recurrent aGCTs.S4. Gene set enrichment analysis results showing that top enriched gene sets are significantly enriched in recurrent tumors in comparison with primary tumors.S5. Boxplot showing the fraction of each noncancerous cell type identified by CIBERSORTx (A) and xCell (B) in primary and recurrent tumor samples.S6. Heatmap showing the correlation between immune cells fractions.
Year:
2025
Immune cell analysis by BMI and sex. A. Immunohistochemistry (IHC) analysis of the MDA cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis of the Gide cohort stratified by BMI and sex. Line represents median +/- interquartile range; each dot represents a single tumor.
Year:
2025
Integrated gene set enrichment analysis of subgroups by body mass index BMI. This figure compares gene expression between overweight/obese (OW/OB) and normal (NL) BMI patients with metastatic melanoma across subgroups by sex, cohort, and tissue site. Supplementary Figure 2 presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients by subgroups. Red indicates upregulation in OW/OB verse NL.
Year:
2025
Integrated gene set enrichment analysis by body mass index (BMI) with correction for S phase. This figure presents a dotplot of genes differentially up- or downregulated in OW/OB patients versus NL BMI patients. Red indicates upregulation in OW/OB verse NL. The far left column is all patients, and then, an analysis controlling for sex, cohort, and tissue site is shown in the 3 columns to the right.
Year:
2025
Inverse Simpson alpha diversity scores of the fecal microbiome by BMI in patients with metastatic melanoma stratified by sex. Box plot represents the median bar with the box bounding the IQR and whiskers the most extreme points within 1.5 x IQR. The red dots represent OW/OB patients and the blue dots represent NL patients by BMI. This is a subgroup analysis of Figure 5C.
Year:
2025
Direct metabolite measurements from a subset of The Cancer Genome Atlas (TCGA) cohort. Comparison of additional tricarboxylic acid cycle metabolites measured by liquid chromatography/mass spectrometry between metastatic melanoma tumors from overweight/obese (OW/OB) patients by body mass index (BMI) verse normal (NL) BMI from The Cancer Genome Atlas (TCGA). Lines represent mean +/- SEM; each dot represents a single tumor.
Year:
2025
Immune cell analysis by BMI. A. Immunohistochemistry (IHC) analysis for CD8-, CD45RO-, FOXP3-, CD68-, GZMB-, PD-1-, LAG-3-, and CD3-positive cells in overweight/obese (OW/OB) verse normal (NL) tumors as defined by body mass index from the MD Anderson Cancer Center (MDA) cohort. Line represents median +/- interquartile range; each dot represents a single tumor. B. IHC analysis for PD-L1-, CD45RO-, FOXP3-, EOMES-, GZMB-, PD-1-, TBET-, and TBET:FOXP3-positive cells in OW/OB verse NL tumors as defined by body mass index from the Gide cohort. Line represents median +/- interquartile range; each dot represents a single tumor.
Year:
2025
Supplementary Table 1: Baseline characteristics for patients included in the integrated gene set enrichment analysis (Figure 2-3) by cohort; Supplementary Table 6: The most frequent somatic alterations (alts) in patients with regionally metastatic melanoma by body mass index from The Cancer Genome Atlas cohort; Supplemental Table 7: Integrated gene set enrichment analysis for pathways associated with fatty acid metabolism by body mass index; Supplemental Table 8: Gene expression of selected genes of interest involved in fatty acid metabolism.
Year:
2025
Beta-diversity analysis stratified by sex based on Bray-Curtis dissimilarity represents microbiome samples with metastatic melanoma in terms of the two top principal components (explaining around 17% of variance) obtained from the principal coordinate analysis. Red dots are from overweight/obese (OW/OB) BMI patients, and blue dots are from normal (NL) BMI patients. Shading inside the dots indicates the female gender. This is a subgroup analysis of Figure 5B.
Year:
2025
Adult type ovarian granulosa cell tumors (AGCT) are rare malignancies with the near universal c.C402G (p.Cys134Trp) somatic mutation in FOXL2 , a forkhead box family transcription factor important for ovarian function. Relapsed AGCT is incurable, but the mechanism of the unique FOXL2 mutation could confer therapeutic vulnerabilities. To identify FOXL2 C134W -dependent pharmacologic synergies, we created and characterized endogenous FOXL2 isogenic AGCT cells and an AGCT tumoroid biobank. A drug screen identified that glucocorticoids promote FOXL2 C134W -dependent AGCT growth. Epigenetic investigation revealed that the Cys134Trp mutation exposes latent DNA sequence–specific chromatin remodeling activity in FOXL2. FOXL2 C134W -dependent chromatin remodeling activity redirected glucocorticoid receptor chromatin occupancy to drive hyaluronan synthase 2 gene expression and increase extracellular hyaluronan secretion. Treatment of AGCT models with hyaluronidase reduced viability, and dexamethasone rescued this effect. Combinatorial drug–drug interaction experiments demonstrated that dexamethasone antagonizes the potency of paclitaxel, a chemotherapy agent frequently used in the treatment of AGCT. Thus, gain-of-function pioneering activity contributes to the oncogenic mechanism of FOXL2 C134W and creates a potentially targetable synergy with glucocorticoid signaling. Significance: Glucocorticoids promote granulosa cell tumor growth via epigenetic coregulation with the disease driver FOXL2 C134W , providing mechanistic insight into disease oncogenesis and uncovering a potential treatment strategy.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (104)
Matthew Campbell
Associate Professor
The University of Texas MD Anderson Cancer Center
Xiuning Le
The University of Texas MD Anderson Cancer Center
David Gerber
Professor of Internal Medicine (Hematology-Oncology) and Clinical Sciences
University of Texas Southwestern Medical Center
Jianjun Zhang
The University of Texas MD Anderson Cancer Center
Michael Green
Professor
The University of Texas MD Anderson Cancer Center
Dinler Antunes
Assistant Professor of Computational Biology
University of Houston
Georgina V. Long
University of Sydney
Mark Davis
Howard Hughes Medical Institute
Kanwal Raghav
Professor
The University of Texas MD Anderson Cancer Center
Lauren Haydu
Assistant Professor of Biostatistics
Mayo Clinic
Carrie Daniel
Professor
The University of Texas MD Anderson Cancer Center
Michael A. Davies
-
Elizabeth Christie
Peter MacCallum Cancer Institute
Hussein A. Abbas
The University of Texas MD Anderson Cancer Center
Jianjun Gao
Assistant Professor
The University of Texas MD Anderson Cancer Center
John Paul Shen
The University of Texas MD Anderson Cancer Center
Ajay Sheshadri
Assistant Professor
The University of Texas MD Anderson Cancer Center
Lauren A. Byers
The University of Texas MD Anderson Cancer Center
Daniel M Halperin
Vice Chair for Clinical Affairs
Winship Cancer Institute of Emory University
Shiro Takamatsu
Associate Lecturer
Kyoto University Hospital
Sung-Eun Lee
-
Chantale Bernatchez
The University of Texas MD Anderson Cancer Center
Ralph J. DeBerardinis
University of Texas Southwestern Medical Center
Samuel Mok
Professor
The University of Texas MD Anderson Cancer Center
Louis Pisters
Professor of Urology
The University of Texas MD Anderson Cancer Center
Melissa Taggart
Associate professor
The University of Texas MD Anderson Cancer Center
Jennifer L. McQuade
The University of Texas MD Anderson Cancer Center
Jun Li
Associate Professor
University of North Carolina at Chapel Hill
Alexander M. Menzies
University of Sydney
Nora M. Navone
Professor
The University of Texas MD Anderson Cancer Center
Theodore S. Nowicki
University of California
Christopher J. Logothetis
The University of Texas MD Anderson Cancer Center
Anil Sood
Professor
The University of Texas MD Anderson Cancer Center
Marina Konopleva
Professor
Albert Einstein College of Medicine
Greg M. Delgoffe
-
Jihoon Kim
Assistant Professor
Yale University
Alejandra Flores Legarreta
The University of Texas MD Anderson Cancer Center
John Kirkwood
Distinguished Service Professor of Medicine
University of Pittsburgh
Clifford Stephan
Research Associate Professor
Texas A&M University Health Sciences Center
David Gershenson
Professor
The University of Texas MD Anderson Cancer Center
Maison Grefe
-
Natalia Baran
Leading attending
University Hospital of Bern
Vashisht Yennu Nanda
Associate Professor
The University of Texas MD Anderson Cancer Center
Junya Fujimoto
Professor and Chair
Hiroshima University Hospital
Jin S. Im
The University of Texas MD Anderson Cancer Center
John Thompson
Clinical Professor
University of Sydney
Samir M. Hanash
The University of Texas MD Anderson Cancer Center
Abel Gonzalez-Perez
Co-PI
IRB Barcelona
Paul Corn
Chair
The University of Texas MD Anderson Cancer Center
Grant Fischer
Assistant Professor of Molecular Genetic Pathology (Tenure Track)
University of North Carolina at Chapel Hill
Francisco Sanchez-Vega
Assistant Attending Computational Biologist
Memorial Sloan Kettering Cancer Center
John V. Heymach
The University of Texas MD Anderson Cancer Center
Koichi Takahashi
The University of Texas MD Anderson Cancer Center
Chao Cheng
Associate Professor
Baylor College of Medicine
J. Jack Lee
Professor
The University of Texas MD Anderson Cancer Center
Reid T Powell
Assistant Professor
Texas A&M University
Seong Gu Heo
Dana-Farber Cancer Institute
Sangeeta Goswami
Associate Professor/ Joint Appointment
The University of Texas MD Anderson Cancer Center
Jennifer A. Wargo
The University of Texas MD Anderson Cancer Center
Elizabeth Burton
The University of Texas MD Anderson Cancer Center
Sreyashi Basu
The University of Texas MD Anderson Cancer Center
Natalie Vokes
The University of Texas MD Anderson Cancer Center
Aditya Mishra
University of Georgia
Michael J. Overman
-
Ryan Sun
Assistant Professor
The University of Texas MD Anderson Cancer Center
Mara B. Antonoff
The University of Texas MD Anderson Cancer Center
Christine Spencer
Parker Institute for Cancer Immunotherapy
Maxime Tarabichi
Group Leader
Université libre de Bruxelles
Cara Haymaker
Associate Professor
The University of Texas MD Anderson Cancer Center
Gheath Alatrash
Professor
The University of Texas MD Anderson Cancer Center
Dirk Schadendorf
University Hospital Essen
Han Liang
The University of Texas MD Anderson Cancer Center
Ana Aparicio
Professor
The University of Texas MD Anderson Cancer Center
R. Tyler Hillman
Associate Professor
UC San Diego Health System
Sumit Subudhi
Assistant Professor
The University of Texas MD Anderson Cancer Center
Patrick Reville
Assistant Professor
The University of Texas MD Anderson Cancer Center
Alexandre Reuben
Assistant Professor
The University of Texas MD Anderson Cancer Center
James Wilmott
Associate Professor
The University of Sydney Library
Simon Heeke
Assistant Professor
The University of Texas MD Anderson Cancer Center
john Davis
Associate Professor
MD Anderson Cancer Center
Sean M Post
The University of Texas MD Anderson Cancer Center
Fatima Zahra Jelloul
The University of Texas MD Anderson Cancer Center
yana najjar
University of Pittsburgh
Edwin J. Ostrin
Associate Professor
The University of Texas MD Anderson Cancer Center
Courtney D. DiNardo
University of Pennsylvania
Alexander Lazar
Professor
The University of Texas MD Anderson Cancer Center
John Ward
Professor
MD Anderson Cancer Center
Suyu Liu
Associate Professor
The University of Texas MD Anderson Cancer Center
Nadim Ajami
Executive Director
The University of Texas MD Anderson Cancer Center
Ken Chen
Professor
The University of Texas MD Anderson Cancer Center
Don L. Gibbons
The University of Texas MD Anderson Cancer Center
Humam Kadara
The University of Texas MD Anderson Cancer Center
Samantha Bersani
University of Verona
Richard A. Scolyer
Faculty Member
University of Sydney
Jia Wu
Associate Professor
The University of Texas MD Anderson Cancer Center
Arif Harmanci
Assistant Professor
The University of Texas Health Science Center at Houston
Nagireddy Putluri
Professor (Tenured)
Baylor College of Medicine
Anke Katharina Bergmann
Director, Chair
University Hospital Würzburg
Linghua Wang
Executive Director & Head
The University of Texas MD Anderson Cancer Center
Jared Burks
Professor
The University of Texas MD Anderson Cancer Center
Christopher Ly
The University of Texas MD Anderson Cancer Center
Guillermo Garcia-Manero
The University of Texas MD Anderson Cancer Center
Naval G. Daver
Professor of Medicine
The University of Texas MD Anderson Cancer Center
Weiyi Peng
Director
University of Houston
Make your next move.
Prepare your application
Review drafts before you send them.